COOPER COMPANIES, INC. COO

Healthcare SIC 3851 - Ophthalmic Goods NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Ophthalmic Goods Manufacturing derived Nasdaq

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year.

Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women's health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8. Financial Statements and Supplementary Data of this Annual Report.

Last close 61.21 2026-10-23
Market cap $11.94B 2026-04-30 share count
52-week range 51.01 - 89.83

Valuation FY2025 figures against the last close

P/S2.9x
P/E32.7x
P/FCF27.5x
EV/EBITDA13.5x
Dividend yield0.0%
Diluted EPS1.87

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Europe
  • Rest of World
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 2.1B (50.2%) 50% United States Europe, FY2025: 1.3B (30.6%) 31% Europe Rest of World, FY2025: 785.2M (19.2%) 19% Rest of World FY2024 United States, FY2024: 2B (50.5%) 50% Europe, FY2024: 1.2B (29.7%) 30% Rest of World, FY2024: 773.6M (19.9%) 20% FY2023 United States, FY2023: 1.8B (50.4%) 50% Europe, FY2023: 1B (29.0%) 29% Rest of World, FY2023: 739.8M (20.6%) 21%
Region FY2025FY2024FY2023
United States $2.05B $1.97B $1.81B
Europe $1.25B $1.16B $1.04B
Rest of World $785.2M $773.6M $739.8M

As the company reported it, from the “Business Segment Information - Schedule of Information by Geographical Area by Country of Domicile (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • Coopervision Segment
  • Coopersurgical Segment
Revenue by segment, 2 categories over 3 years. The same figures are in the table below. FY2025 Coopervision Segment, FY2025: 2.7B (67.0%) 67% Coopervision Segment Coopersurgical Segment, FY2025: 1.3B (33.0%) 33% Coopersurgical Segment FY2024 Coopervision Segment, FY2024: 2.6B (67.0%) 67% Coopersurgical Segment, FY2024: 1.3B (33.0%) 33% FY2023 Coopervision Segment, FY2023: 2.4B (67.5%) 67% Coopersurgical Segment, FY2023: 1.2B (32.5%) 33%
Segment FY2025FY2024FY2023
Coopervision Segment $2.74B $2.61B $2.42B
Coopersurgical Segment $1.35B $1.29B $1.17B

As the company reported it, from the “Business Segment Information - Schedule of Business Segment Net Sales (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $4.09B$3.90B$3.59B$3.31B$2.92B$2.43B$2.65B$2.53B$2.14B$1.97B
Cost of revenue $1.41B$1.30B$1.24B$1.17B$966.7M$896.1M$896.6M$900.5M$773.2M$793.7M
Gross profit $2.68B$2.60B$2.36B$2.14B$1.96B$1.53B$1.76B$1.63B$1.37B$1.17B
R&D $172.2M$155.1M$137.4M$110.3M$92.7M$93.3M$86.7M$84.8M$69.2M$65.4M
SG&A $1.63B$1.53B$1.50B$1.34B$1.21B$992.5M$996.2M$973.3M$799.1M$722.8M
Operating income $682.9M$705.7M$533.1M$507.6M$505.8M$311.8M$546.7M$403.1M$429.1M$324.1M
Interest expense $100.0M$114.3M$105.3M$57.3M$23.1M$36.8M$68.0M$82.7M$33.4M$26.2M
Pre-tax income $566.5M$582.3M$412.9M$475.3M$491.5M$266.5M$477.4M$331.9M$394.0M$295.6M
Income tax $191.6M$190.0M$118.7M$89.5M$2.45B$28.1M$10.7M$192.0M$21.1M$20.7M
Net income $374.9M$392.3M$294.2M$385.8M$2.94B$238.4M$466.7M$139.9M$372.9M$273.9M
EPS, basic 1.881.971.491.9559.804.859.442.857.635.65
EPS, diluted 1.871.961.481.9459.164.819.332.817.525.59
Shares, diluted (wtd. avg.) 200.0M200.4M199.3M198.8M49.8M49.6M50.0M49.7M49.6M49.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $110.6M$107.6M$120.8M$138.6M$96.6M$116.8M$89.5M$80.2M$88.8M$100.8M
Receivables $829.0M$717.0M$609.7M$557.8M$515.3M$435.4M$435.3M$374.7M$316.6M$291.4M
Inventory $846.0M$802.7M$735.6M$628.7M$585.6M$570.4M$506.9M$468.8M$454.1M$417.7M
Total current assets $2.11B$1.95B$1.70B$1.53B$1.47B$1.27B$1.16B$1.09B$953.2M$937.1M
Property, plant and equipment $2.08B$1.86B$1.63B$1.41B$1.35B$1.28B$1.13B$976.0M$910.1M$877.7M
Goodwill $3.85B$3.84B$3.62B$3.61B$2.57B$2.45B$2.43B$2.39B$2.35B$2.16B
Other intangibles $1.59B$1.79B$1.71B$1.89B$1.27B$1.29B$1.41B$1.52B$504.7M$441.1M
Total assets $12.39B$12.32B$11.66B$11.49B$9.61B$6.74B$6.27B$6.11B$4.86B$4.48B
Accounts payable $300.4M$260.5M$261.9M$248.8M$161.4M$176.0M$150.1M$146.4M$142.1M$107.4M
Short-term debt $47.8M$33.3M$45.4M$412.6M$83.4M$409.3M$563.7M$37.1M$23.4M$210.7M
Total current liabilities $1.11B$1.02B$969.0M$1.28B$732.1M$1.00B$1.11B$536.5M$396.1M$543.2M
Long-term debt $2.46B$2.55B$2.52B$2.35B$1.40B$1.38B$1.26B$1.99B$1.15B$1.11B
Total liabilities $4.16B$4.23B$4.11B$4.32B$2.66B$2.91B$2.65B$2.81B$1.68B$1.78B
Retained earnings $7.64B$7.27B$6.88B$6.58B$6.20B$3.26B$3.03B$2.58B$2.43B$2.05B
Total equity $8.24B$8.08B$7.55B$7.17B$6.94B$3.82B$3.63B$3.31B$3.18B$2.70B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $796.1M$709.3M$607.5M$692.4M$738.6M$486.6M$713.2M$668.9M$593.6M$509.6M
Depreciation and amortisation $377.4M$375.1M$367.7M$346.1M$309.3M$149.9M$135.0M$128.4M$188.4M$198.3M
Stock-based compensation $70.5M$75.1M$62.1M$54.2M$43.8M$37.6M$35.1M$43.2M$37.2M$29.9M
Capital expenditure $362.4M$421.2M$392.5M$242.0M$214.4M$310.4M$292.1M$193.6M$127.2M$152.6M
Investing cash flow -$372.9M-$764.6M-$449.0M-$1.83B-$450.3M-$364.5M-$351.3M-$1.52B-$381.3M-$418.7M
Financing cash flow -$425.9M$39.2M-$173.9M$1.19B-$311.4M-$95.5M-$351.4M$844.4M-$227.9M-$1.4M
Dividends paid $0$0$3.0M$3.0M$3.0M$3.0M$3.0M$2.9M$2.9M$2.9M
Buybacks $290.1M$0$0$78.5M$24.8M$47.8M$156.1M$0$55.0M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-25-055615.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B Revenue, FY2016: 2B Gross profit, FY2016: 1.2B Net income, FY2016: 273.9M Revenue, FY2017: 2.1B Gross profit, FY2017: 1.4B Net income, FY2017: 372.9M Revenue, FY2018: 2.5B Gross profit, FY2018: 1.6B Net income, FY2018: 139.9M Revenue, FY2019: 2.7B Gross profit, FY2019: 1.8B Net income, FY2019: 466.7M Revenue, FY2020: 2.4B Gross profit, FY2020: 1.5B Net income, FY2020: 238.4M Revenue, FY2021: 2.9B Gross profit, FY2021: 2B Net income, FY2021: 2.9B Revenue, FY2022: 3.3B Gross profit, FY2022: 2.1B Net income, FY2022: 385.8M Revenue, FY2023: 3.6B Gross profit, FY2023: 2.4B Net income, FY2023: 294.2M Revenue, FY2024: 3.9B Gross profit, FY2024: 2.6B Net income, FY2024: 392.3M Revenue, FY2025: 4.1B Gross profit, FY2025: 2.7B Net income, FY2025: 374.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.97B $2.14B $2.53B $2.65B $2.43B $2.92B $3.31B $3.59B $3.90B $4.09B
Gross profit $1.17B $1.37B $1.63B $1.76B $1.53B $1.96B $2.14B $2.36B $2.60B $2.68B
Net income $273.9M $372.9M $139.9M $466.7M $238.4M $2.94B $385.8M $294.2M $392.3M $374.9M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement signed Item 1.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3851

TickerCompanyMarket capP/ERevenue growth
BLCO Bausch & Lomb Corp $6.24B — 6.5%
WRBY Warby Parker Inc. $3.21B 2,591.0x 13.0%
EYE National Vision Holdings, Inc. $1.48B 50.5x 9.0%
STAA STAAR SURGICAL CO $1.13B — -23.7%
RXST RxSight, Inc. $208.8M — -3.9%
LUCY Innovative Eyewear Inc $7.5M — 62.6%
ALC ALCON INC — — 4.9%